Zevra Therapeutics (NASDAQ:ZVRA) Trading Up 5.9% - Should You Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) shares traded up 5.9% during trading on Thursday . The company traded as high as $9.91 and last traded at $9.97. 224,411 shares traded hands during trading, a decline of 67% from the average session volume of 679,418 shares. The stock had previously closed at $9.41.

Analysts Set New Price Targets

ZVRA has been the subject of a number of research analyst reports. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. HC Wainwright assumed coverage on Zevra Therapeutics in a research report on Wednesday. They set a "buy" rating and a $26.00 target price for the company. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Zevra Therapeutics presently has a consensus rating of "Buy" and an average target price of $23.14.

Zevra Therapeutics Price Performance

The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02. The firm has a fifty day simple moving average of $8.57 and a 200 day simple moving average of $8.09. The company has a market capitalization of $535.04 million, a PE ratio of -5.15 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same quarter in the prior year, the company earned ($0.40) EPS. Equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new stake in shares of Zevra Therapeutics in the 4th quarter valued at about $53,000. GAMMA Investing LLC boosted its stake in shares of Zevra Therapeutics by 20,564.1% during the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock valued at $60,000 after purchasing an additional 8,020 shares in the last quarter. Strs Ohio purchased a new position in Zevra Therapeutics during the first quarter valued at approximately $125,000. Squarepoint Ops LLC increased its holdings in Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after buying an additional 4,384 shares during the period. Finally, ProShare Advisors LLC bought a new position in Zevra Therapeutics in the fourth quarter worth approximately $145,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.